Opioid use in pregnancy has increased in parallel to the opioid crisis observed in the general population. Rising rates of peripartum opioid use pose a significant public health concern for both mothers and their children. Pregnancy also represents a unique opportunity for healthcare providers to screen women for opioid use disorder and engage them in appropriate care. In the present review, we describe patterns of opioid use in pregnancy and how this relates to maternal and neonatal health outcomes. We also examine screening for and treatment of opioid use disorder in pregnancy, neonatal outcomes following maternal opioid use, and breastfeeding recommendations for women taking opioids postpartum.
GomesTTadrousMMamdaniMM, et al.
The burden of opioid-related mortality in the United States. JAMA Netw Open2018;
1: e180217.
2.
RuddRASethPDavidF, et al.
Increases in drug and opioid-involved overdose deaths – United States, 2010-2015. MMWR Morb Mortal Wkly Rep2016;
65: 1445–1452.
BrummettCMWaljeeJFGoeslingJ, et al.
New persistent opioid use after minor and major surgical procedures in US adults. JAMA Surg2017;
152: e170504.
5.
GomesTMamdaniMMPatersonJM, et al.
Trends in high-dose opioid prescribing in Canada. Can Fam Physician2014;
60: 826–832.
6.
AilesECDawsonALLindJN, et al.
Opioid prescription claims among women of reproductive age–United States. MMWR Morb Mortal Wkly Rep2015;
64: 2008–2012.
7.
DesaiRJHernandez-DiazSBatemanBT, et al.
Increase in prescription opioid use during pregnancy among Medicaid-enrolled women. Obstet Gynecol2014;
123: 997–1002.
8.
PatrickSWSchumacherREBenneyworthBD, et al.
Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA2012;
307: 1934–1940.
9.
TurnerSDGomesTCamachoX, et al.
Neonatal opioid withdrawal and antenatal opioid prescribing. C Open 2015;
3: E55–61.
10.
BaldiniAVKorffMLinEHB.A review of potential adverse effects of long-term opioid therapy: a practitioner’s guide. Prim Care Companion CNS Disord2012;
14.
11.
MaedaABatemanBTClancyCR, et al.
Opioid abuse and dependence during pregnancy: temporal trends and obstetrical outcomes. Anesthesiology2014;
121: 1158–1165.
12.
WongSOrdeanAKahanM, et al.SOGC clinical practice guidelines: Substance use in pregnancy: no. 256, April 2011. Int J Gynaecol Obstet2011;
114: 190–202.
Coleman-CowgerVHOgaEAPetersEN, et al.
Accuracy of three screening tools for prenatal substance use. Obstet Gynecol2019;
133: 952–961.
15.
OndersmaSJChangGBlake‐LambT, et al.
Accuracy of five self‐report screening instruments for substance use in pregnancy. Addiction2019;
114: 1683–1693.
16.
Center for Substance Abuse Treatment.
Medication-assisted treatment for opioid addiction during pregnancy. Treatment Improvement Protocol (TIPS) Series. Subst Abus Ment Heal Serv Adm2005;
43: 211–224.
17.
ZedlerBKMannALKimMM, et al.
Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child. Addiction2016;
111: 2115–2128.
18.
MinozziSAmatoLBellisarioC, et al.
Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database Syst Rev2013.
19.
BroglySBSaiaKAWalleyAY, et al.
Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis. Am J Epidemiol2014;
180: 673–686.
20.
DebelakKMorroneWRO’GradyKE, et al.
Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data. Am J Addict 2013;
22: 252–254.
21.
WiegandSLStringerEMStuebeAM, et al.
Buprenorphine and naloxone compared with methadone treatment in pregnancy. Obstet Gynecol2015;
125: 363–368.
22.
AlfordDPComptonPSametJH.Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med2006;
144: 127–134.
23.
HudakMLTanRC,
Committee on Drugs, et al. Neonatal drug withdrawal. Pediatrics2012;
129: e540–560.
24.
KällénBBorgNReisM.The use of central nervous system active drugs during pregnancy. Pharmaceuticals (Basel)2013;
6: 1221–1286.
25.
KellyLDooleyJCromartyH, et al.
Narcotic-exposed neonates in a First Nations population in northwestern Ontario: incidence and implications. Can Fam Physician2011;
57: e441.
26.
LudlowJPEvansSFHulseG.Obstetric and perinatal outcomes in pregnancies associated with illicit substance abuse. Aust N Z J Obstet Gynaecol2004;
44: 302–306.
27.
ClearyBJDonnellyJMStrawbridgeJD, et al.
Methadone and perinatal outcomes: a retrospective cohort study. Am J Obstet Gynecol2011;
204: 139.e1–9.
28.
GreigEAshADouiriA.Maternal and neonatal outcomes following methadone substitution during pregnancy. Arch Gynecol Obstet2012;
286: 843–851.
29.
BurnsLConroyEMattickRP.Infant mortality among women on a methadone program during pregnancy. Drug Alcohol Rev2010;
29: 551–556.
30.
BaldacchinoAArbuckleKPetrieDJ, et al.
Neurobehavioral consequences of chronic intrauterine opioid exposure in infants and preschool children: a systematic review and meta-analysis. BMC Psychiatry2014;
14: 104.
31.
BrackenMBHolfordTR.Exposure to prescribed drugs in pregnancy and association with congenital malformations. Obstet Gynecol1981;
58: 336–344.
32.
BroussardCSRasmussenSAReefhuisJ, et al.
Maternal treatment with opioid analgesics and risk for birth defects. Am J Obstet Gynecol2011;
204: 314.e1–11.
33.
YazdyMMMitchellAATinkerSC, et al.
Periconceptional use of opioids and the risk of neural tube defects. Obstet Gynecol2013;
122: 838–844.
34.
Nezvalová-HenriksenKSpigsetONordengH.Effects of codeine on pregnancy outcome: results from a large population-based cohort study. Eur J Clin Pharmacol2011;
67: 1253–1261.
35.
FishmanBDanielSKorenG, et al.
Pregnancy outcome following opioid exposure: a cohort study. PLoS One2019;
14: e0219061.
36.
ShortTDStallingsEBIsenburgJ, et al.
Gastroschisis trends and ecologic link to opioid prescription rates – United States, 2006-2015. MMWR Morb Mortal Wkly Rep2019;
68: 31–36.
37.
KyriacouDNLewisRJ.Confounding by indication in clinical research. JAMA2016;
316: 1818–1819.
38.
McQueenKMurphy-OikonenJ.Neonatal abstinence syndrome. N Engl J Med2016;
375: 2468–2479.
39.
PallaMRKhanGHaghighatZM, et al.
EEG findings in infants with neonatal abstinence syndrome presenting with clinical seizures. Front Pediatr2019;
7: 111.
KoJYPatrickSWTongVT, et al.
Incidence of neonatal abstinence syndrome – 28 States, 1999-2013. MMWR Morb Mortal Wkly Rep2016;
65: 799–802.
42.
WinkelmanTNAVillapianoNKozhimannilKB, et al.
Incidence and costs of neonatal abstinence syndrome among infants with Medicaid. Pediatrics2018;
141: 2004–2014.
43.
StrahanAEGuyGPBohmM, et al.
Neonatal abstinence syndrome incidence and health care costs in the United States, 2016. JAMA Pediatr2020;
174: 200.
44.
HuybrechtsKFBatemanBTDesaiRJ, et al.
Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: cohort study. BMJ2017;
358: j3326.
45.
Moses-KolkoELBogenDPerelJ, et al.
Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA2005;
293: 2372–2383.
46.
SanlorenzoLAStarkARPatrickSW.Neonatal abstinence syndrome: an update. Curr Opin Pediatr2018;
30: 182–186.
47.
HolmesAVAtwoodECWhalenB, et al.
Rooming-in to treat neonatal abstinence syndrome: improved family-centered care at lower cost. Pediatrics2016;
137.
48.
KraftWKAdeniyi-JonesSCChervonevaI, et al.
Buprenorphine for the treatment of the neonatal abstinence syndrome. N Engl J Med2017;
376: 2341–2348. doi:10.1056/NEJMoa1614835
49.
BadreldinNGrobmanWAChangKT, et al.
Opioid prescribing patterns among postpartum women. Am J Obstet Gynecol2018.
50.
BatemanBTColeNMMaedaA, et al.
Patterns of opioid prescription and use after cesarean delivery. Obstet Gynecol2017;
130: 29–35.
51.
OsmundsonSSSchornackLAGraschJL, et al.
Postdischarge opioid use after cesarean delivery. Obstet Gynecol2017;
130: 36–41.
52.
PrabhuMMcQuaid-HansonEHoppS, et al.
A shared decision-making intervention to guide opioid prescribing after cesarean delivery. Obstet Gynecol2017;
130: 42–46.
53.
OsmundsonSSMinJYWieseAD, et al.
Opioid prescribing after childbirth and risk for serious opioid-related events: a cohort study. Ann Intern Med2020.
54.
PeahlAFDaltonVKMontgomeryJR, et al.
Rates of new persistent opioid use after vaginal or cesarean birth among US women. JAMA Netw Open2019;
2: e197863.
55.
ItoS.Opioids in breast milk: pharmacokinetic principles and clinical implications. J Clin Pharmacol2018;
58: S151–S163.
56.
CritchJN.Canadian Paediatric Society N and GC. Nutrition for healthy term infants, birth to six months: an overview. Paediatr Child Health2013;
18: 206–209.
57.
KorenGCairnsJChitayatD, et al.
Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet2006;
368: 704.
58.
MadadiPKorenGCairnsJ, et al.
Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Can Fam Physician2007;
53: 33–35.
59.
FernerRE.Did the drug cause death? Codeine and breastfeeding. Lancet2008;
372: 606–608.
60.
WillmannSEdgintonANCoboekenK, et al.
Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study. Clin Pharmacol Ther2009;
86: 634–643.
61.
BatemanDNEddlestonMSandilandsE.Codeine and breastfeeding. Lancet2008;
372: 625–626.
62.
YoungM.Morphine in breast milk. Can Fam Physician2007;
53: 1005; author reply 1005–1006.
63.
ZipurskyJJuurlinkDN.The implausibility of neonatal opioid toxicity from breastfeeding. Clin Pharmacol Ther2020.
SmolinaKWeymannDMorganS, et al.
Association between regulatory advisories and codeine prescribing to postpartum women. JAMA2015;
313: 1861–1862.
68.
FinkelsteinYMacdonaldEMGonzalezA, et al.
Overdose risk in young children of women prescribed opioids. Pediatrics2017;
139.
69.
JuurlinkDNGomesTGuttmannA, et al.
Postpartum maternal codeine therapy and the risk of adverse neonatal outcomes: a retrospective cohort study. Clin Toxicol (Phila)2012;
50: 390–395.
70.
DieterichCMFeliceJPO’SullivanE, et al.
Breastfeeding and health outcomes for the mother-infant dyad. Pediatr Clin North Am2013;
60: 31–48.
71.
British Columbia Centre on Substance Use, B.C. Ministry of Health BCM of, Mental Health and Addictions & PSB. Guideline for the clinical management of opioid use disorder—pregnancy supplement. 2018; 1–32. www.bccsu.ca/care-guidance-%0Apublications/
